Responses
Epidemiology/Health Services Research
Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Compose a Response to This Article
Other responses
No responses have been published for this article.